TB-006

N/A

Report date: 2025/03/13 15:11:03

Base Information

Drug NameTB-006
Drug Alias NameAnti-TIM-3 monoclonal antibodyTB-006TB006
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsHepatitis A virus cellular receptor 2 inhibitorsT lymphocytes stimulants
TargetsHepatitis A virus cellular receptor 2
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Ischemic StrokeAutism Spectrum Disorder +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTrueBinding Inc
China Registration ClassN/A

Develop Information

Active CompaniesRossignol Medical CenterTrueBinding Inc
Inactive CompaniesN/A
Active IndicationsAutism Spectrum DisorderAlzheimer DiseaseParkinson Disease
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Ischemic Stroke

Other Information

ATC CodeN/A
Related LinksN/A